EyeGate Pharmaceuticals reported a net loss of $2.78 million in the second quarter of 2018, compared to a net loss of $3.327 million in the second quarter of 2018.
Research and development costs decreased from $2.262 million in 2017’s second quarter to $1.838 million in 2018, due to decreases in clinical activity for the company’s post cataract surgery inflammation and pain treatment EGP-437, according to a company press release.
General and administrative expenses were $1.203 million for the quarter compared to 2017’s second quarter expenses of $1.213 million.
EyeGate had cash
Uncategorized